<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00015834</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02374</org_study_id>
    <secondary_id>UCLA-0011009</secondary_id>
    <secondary_id>CDR0000068441</secondary_id>
    <nct_id>NCT00015834</nct_id>
  </id_info>
  <brief_title>STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia</brief_title>
  <official_title>A Phase I/II Trial of STI571 and High-Dose Cytarabine in Myeloid Blast Crisis of Chronic Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase I/II trial to study the effectiveness of combining STI571 and chemotherapy in treating&#xD;
      patients who have chronic myelogenous leukemia. Drugs used in chemotherapy use different ways&#xD;
      to stop cancer cells from dividing so they stop growing or die. STI571 may stop the growth of&#xD;
      leukemia cells. Combining chemotherapy and STI571 may kill more cancer cells&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose of high-dose cytarabine when combined with imatinib&#xD;
      mesylate in patients with blastic phase chronic myelogenous leukemia.&#xD;
&#xD;
      II. Determine the safety of this regimen in these patients. III. Determine the&#xD;
      pharmacokinetics of this regimen in these patients. IV. Determine the frequency of&#xD;
      hematologic and cytogenetic responses, duration of response, and survival of patients treated&#xD;
      with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of cytarabine.&#xD;
&#xD;
      Phase I: Patients who have not previously received imatinib mesylate receive oral imatinib&#xD;
      mesylate daily on days 1-35. Patients who have previously received imatinib mesylate for at&#xD;
      least 28 days receive oral imatinib mesylate on days 22-35. All patients receive cytarabine&#xD;
      IV over 2 hours every 12 hours on days 29-32. Patients with more than 5% residual blasts in&#xD;
      bone marrow on day 28 receive a second course in the absence of disease progression or&#xD;
      unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of cytarabine until&#xD;
      the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that&#xD;
      which 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Phase II: Additional patients are treated at the dose level preceding the MTD. Patients are&#xD;
      followed monthly.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <primary_completion_date type="Actual">April 2003</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity according to NCI/NIH Common Toxicity Criteria</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Described by duration, relatedness to treatment, and action taken.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hematologic response</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone marrow cytogenetic response</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Blastic Phase Chronic Myelogenous Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Relapsing Chronic Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (imatinib mesylate, cytarabine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who have not previously received imatinib mesylate receive oral imatinib mesylate daily on days 1-35. Patients who have previously received imatinib mesylate for at least 28 days receive oral imatinib mesylate on days 22-35. All patients receive cytarabine IV over 2 hours every 12 hours on days 29-32. Patients with more than 5% residual blasts in bone marrow on day 28 receive a second course in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (imatinib mesylate, cytarabine)</arm_group_label>
    <other_name>CGP 57148</other_name>
    <other_name>Gleevec</other_name>
    <other_name>Glivec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (imatinib mesylate, cytarabine)</arm_group_label>
    <other_name>ARA-C</other_name>
    <other_name>arabinofuranosylcytosine</other_name>
    <other_name>arabinosylcytosine</other_name>
    <other_name>Cytosar-U</other_name>
    <other_name>cytosine arabinoside</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of chronic myelogenous leukemia in myeloid blast crisis&#xD;
&#xD;
               -  At least 30% blasts in bone marrow&#xD;
&#xD;
          -  Philadelphia chromosome positive by cytogenetic analysis&#xD;
&#xD;
          -  bcr/abl translocation by fluorescent in situ hybridization&#xD;
&#xD;
          -  Ineligible for or refused allogeneic stem cell transplantation&#xD;
&#xD;
          -  Not previously treated with imatinib mesylate OR currently receiving imatinib mesylate&#xD;
             with stable disease on 2 bone marrow biopsies at least 2 weeks apart&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Bilirubin less than 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT less than 3 times ULN&#xD;
&#xD;
          -  Creatinine less than 2 times ULN&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception during and for at least 2&#xD;
             weeks after study for female patients and at least 3 months after study for male&#xD;
             patients&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior allogeneic bone marrow or peripheral blood stem cell transplantation&#xD;
&#xD;
          -  At least 48 hours since prior interferon alfa&#xD;
&#xD;
          -  At least 24 hours since prior hydroxyurea&#xD;
&#xD;
          -  At least 6 weeks since prior busulfan&#xD;
&#xD;
          -  No other prior chemotherapy for blast crisis (except hydroxyurea)&#xD;
&#xD;
          -  Concurrent hydroxyurea or anagrelide for severe leukocytosis or thrombocytosis allowed&#xD;
&#xD;
          -  At least 4 weeks since prior investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Paquette</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California at Los Angeles (UCLA )</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California at Los Angeles (UCLA )</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>May 6, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Blast Crisis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

